This image is a representation. Your design will be featured in the final product.

Warning: The information provided on this page is for general knowledge purposes only and does not replace the official Instructions for Use (IFU), which are supplied with the medical device. This page does not constitute an electronic IFU either.

MIG SPRAY : preventive treatment of episodic migraines

MIG SPRAY is an innovative, nasally-applied medical product designed to alleviate both frequency and severity of episodic migraines. It works through an osmotic mechanism that draws out fluids and irritants, effectively cleaning the nasal mucosa and relieving nasal congestion, directly targeting the mechanisms that trigger and substain migraines. Additionally, it forms a protective barrier that helps block external triggers known to induce migraines.

This unique formulation is composed of over 98% natural-origin ingredients, ensuring a high-quality product that combines efficacy with excellent safety.

Its effectiveness and safety have been confirmed through three clinical studies, showing efficacy from the second month of treatment.

Clinical trial

Randomized, double-blind, placebo-controlled trial

Population

This product is intended for adult and children aged seven (7) years and older use.

Indication

Preventive treatment for episodic migraines, with or without aura.

MIG SPRAY was developed in collaboration with the European migraine research center NEURO-DOL (Inserm, CHU de Clermont-Ferrand).

Patient's benefits

Reduction of migraine associated-pain
Reduced impairment/disability associated with migraine
Improved daily functioning / functionality - Improved quality of life
Reduces dependency on acute crisis medication

These benefits are supported by clinical studies demonstrating that MIG SPRAY significantly reduces the frequency and severity of migraine attacks, which contributes to its overall impact on the management of episodic migraine.

Product development and research

MIG SPRAY was developed through extensive research into the role of nasal mucosa in migraine pathogenesis. Its formulation leverages an osmotic effect to draw triggering factors away from the nasal lining into an osmotically active solution. This osmotic action also cleanses the nasal cavity and sinuses, helping to relieve nasal congestion and directly addressing the mechanisms involved in migraine attacks.

Mode of action

MIG SPRAY is a nasal spray that helps prevent migraines through two mechanical actions:

Osmotic Decongestion: The glycerol solution gently cleanses and decongests the nasal passages by drawing out excess mucus and impurities. This contributes to a more stable and less reactive nasal environment, helping to reduce overstimulation of nerve endings involved in the onset and persistence of migraines.
Protective Barrier: When used, MIG SPRAY forms a gentle layer inside your nose. This barrier helps to block out external triggers such as chemicals, pollutants and irritants that can trigger a migraine.

MIG SPRAY is a promising preventive treatment for migraines. Its unique mechanism of action, combined with clinical evidence demonstrating its efficacy and safety, make it a valuable addition to the therapeutic options for migraine management. Future research can further shed light on its potential applications and benefits.

Clinical studies

MIG SPRAY has demonstrated strong clinical efficacy and safety across multiple studies. In a randomised controlled trial involving 125 adults, it led to a 23% reduction in migraine frequency after 3 months, with 22% of patients achieving at least a 50% reduction in attacks. It also resulted in a 40% decrease in migraine intensity, a 50% reduction in triptan use, and significant improvements in HIT-6 and MIDAS scores.

A real-life study with 322 patients confirmed these findings, showing a 26% reduction in migraine days, along with improvements in intensity, duration, and overall quality of life.

In children aged 7 and above, a separate clinical study showed a significant reduction in migraine frequency with no reported adverse effects.

Across all studies, MIG SPRAY was well tolerated and safe, making it a reliable non-drug preventive option for both adults and children suffering from episodic migraines.

Product Details

Indication: Used for the prevention of episodic migraines, with or without aura, in adults and children aged seven (7) years and older.
Composition: Made from natural-origin ingredients
Presentation: 15ml Nasal spray.
Class: MDR Class IIa.
Age: 7+.
Storage conditions: Below 25°C.
Legal manufacturer: VITROBIO (France).
Product code: MIG.